Beilstein J. Nanotechnol.2022,13, 1393–1407, doi:10.3762/bjnano.13.115
third most lethal cancers globally, beginning as polyps in the intestine and spreading with a severe metastatic tendency. Chemotherapeutic drugs used in the treatment of intestinaltumors are usually formulated for parenteral administration due to poor solubility and bioavailability problems
. Pharmaceutically, clinical failure due to a drug’s wide biodistribution and non-selective toxicity is one of the major challenges of chemotherapy. In addition, parenteral drug administration in chronic diseases that require long-term drug use, such as intestinaltumors, is challenging in terms of patient
studies on the Caco-2 cell line, the CS/DCX-PLGA formulation increased permeability by 383% compared to free DCX (p < 0.05). In the light of all results, CS/DCX-PLGA NPs can offer a promising and innovative approach as an oral anticancer drug-loaded nanoformulation for intestinaltumors.
Keywords
PDF
Figure 1:
SEM images of the DCX loaded nanoparticle formulations.